PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
22736026-10	2012	CONCLUSIONS: Our study first found that beta-elemene could increase the expression of HIF-1alpha through ROS and PI3K/Akt/mTor signaling pathway.	beta-elemene	40-52	mechanistic target of rapamycin kinase	Homo sapiens	122-126	
26863884-3	2016	beta-elemene exerts therapeutic potential via modulation of core hallmark capabilities of cancer by suppressing proliferative signaling, such as MAPK and PI3K/Akt/mTOR pathway, inducing cell death, up-regulating growth suppressors, deactivating invasion and metastasis and interacting replicative immortality and attenuating angiogenesis.	beta-elemene	0-12	mechanistic target of rapamycin kinase	Homo sapiens	163-167	
24146496-0	2013	The effects of beta-elemene on the expression of mTOR, HIF-1A, survivin in lung adenocarcinoma A549 cell.	beta-elemene	15-27	mechanistic target of rapamycin kinase	Homo sapiens	49-53	
23761818-0	2013	13,14-bis(cis-3,5-dimethyl-1-piperazinyl)-beta-elemene, a novel beta-elemene derivative, shows potent antitumor activities via inhibition of mTOR in human breast cancer cells.	beta-elemene	42-54	mechanistic target of rapamycin kinase	Homo sapiens	141-145	
22150682-8	2012	Further study showed that beta-elemene inhibited the activity of the PI3K/Akt/mTOR/p70S6K1 signalling pathway, and at the same time it triggered a robust autophagy.	beta-elemene	26-38	mechanistic target of rapamycin kinase	Homo sapiens	78-82	
22150682-11	2012	CONCLUSIONS: Our data indicated that beta-elemene inhibited the activity of the PI3K/Akt/mTOR/p70S6K1 signalling pathway in human NSCLC A549 cells, which resulted in apoptosis as well as protective autophagy.	beta-elemene	37-49	mechanistic target of rapamycin kinase	Homo sapiens	89-93	
21595977-8	2011	PI3K/Akt/mTOR/p70S6K1 activity was inhibited by beta-elemene.	beta-elemene	48-60	mechanistic target of rapamycin kinase	Homo sapiens	9-13	
16617020-0	2006	The synthesis and anti-proliferative effects of beta-elemene derivatives with mTOR inhibition activity.	beta-elemene	48-60	mechanistic target of rapamycin kinase	Homo sapiens	78-82	
30422809-7	2019	beta-elemene significantly suppressed the insulin-driven cell growth and the activation of mTOR and PI3K in tumor cells, while the toxicity to normal hepatocytes is much lower.	beta-elemene	0-12	mechanistic target of rapamycin kinase	Homo sapiens	91-95	
22938451-0	2012	beta-Elemene induces apoptosis in human renal-cell carcinoma 786-0 cells through inhibition of MAPK/ERK and PI3K/Akt/ mTOR signalling pathways.	beta-elemene	0-12	mechanistic target of rapamycin kinase	Homo sapiens	118-122	
22938451-9	2012	Further study showed that beta-elemene inhibited the MAPK/ERK as well as PI3K/Akt/mTOR signalling pathways.	beta-elemene	26-38	mechanistic target of rapamycin kinase	Homo sapiens	82-86	
33758606-6	2021	Compared with erlotinib alone, beta-elemene plus erlotinib significantly promoted the apoptosis of NCI-H1975 cells, accompanied by the down-regulated expression of P-mTOR, P-EGFR, CHOP proteins and up-regulated expression of P-AMPKalpha and Bax proteins.	beta-elemene	31-43	mechanistic target of rapamycin kinase	Homo sapiens	166-170	
30912190-4	2019	We have individually summarized regulation of tumor necrosis factor related apoptosis-inducing ligand, signal transducers and activators of transcription, transforming growth factor/SMAD, NOTCH, and mammalian target of rapamycin pathways by beta-elemene.	beta-elemene	241-253	mechanistic target of rapamycin kinase	Homo sapiens	199-228	
30422809-5	2019	beta-elemene in combination with IGF1R inhibitors enhanced markedly the repression on cellular proliferation and mTOR activation by IGF1R inhibitors, and suppressed the PI3K phosphorylation induced by IGF1R inhibitors.	beta-elemene	0-12	mechanistic target of rapamycin kinase	Homo sapiens	113-117